Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression - Full Text View

Sponsor:	Vanderbilt University
Collaborator:	Janssen Pharmaceutica N.V., Belgium
Information provided by:	Vanderbilt University
ClinicalTrials.gov Identifier:	NCT00179244

Purpose

The purpose of this study is to evaluate the comparative effectiveness of Risperdal (risperidone) or bupropion ER (extended release) combined with a SSRI medication and to test the relative safety of the combinations.

Condition	Intervention	Phase
Unipolar Depression	Drug: Rispridone (drug) and Bupropion ER (drug)	Phase III

Study Type:	Interventional
Study Design:	Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study
Official Title:	Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression

Resource links provided by NLM:

MedlinePlus related topics: Depression

Drug Information available for: Bupropion hydrochloride Bupropion Risperidone

U.S. FDA Resources

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:

MADRS (Montgomery Asberg's Depression Rating Scale)

Secondary Outcome Measures:

HAM-D(Hamilton Rating Scale for Depression ) 17-item
BDI (Beck Depression Inventory)
HAM-A (Hamilton Rating Scale for Anxiety)
Clinical Global Impression Scale and Severity and Improvement.

Estimated Enrollment:	30
Study Start Date:	July 2004
Study Completion Date:	April 2005

Detailed Description:

Major depression is a severe disorder with serious consequences. Effective treatments are available; however, in clinical trials 30-40% of patients do not experience even a 50% reduction in depression severity scores, while 50-70% fail to achieve a full therapeutic response. Futhermore, impairment from the disorder continues essentially unabated in patients who are treated but do not fully remit. If anything, the situation is at least as bad or not worse in clinical practice. Clearly, alternatives are needed to manage this common clinical condition.

The addition of bupropion ER (extended release) to an SSRI has empirical support, and has become the most common augmentation strategy in the US. A comparative trial of the combination of risperidone or bupropion ER added to an SSRI in treatment resistant deperssion could help support risperidone for this condition; such a trial seems warranted at this time.

Patients who are currently on a SSRI at an adequate dosage for at least 3 weeks with no response, will be randomly assigned (open-label) to either risperidone or bupropion ER augmentation for a period of 6 weeks. Patients will be followed weekly at the beginning and bi-weekly towards the end of the trial to compare the response of each group.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female 18 years or older
DSM-IV diagnosis of major depressive disorder of at least moderate severity, but without psychotic features
Ham-D 17 score of 18 or above
Have a documentable history of 2 prior adequate trials of antidepressants including an SSRI without sufficient response. A clinically adequate trial is defined as having taken a minimum effective dose of an antidepressant for at least 3 weeks without a significant change in depressive symptoms.
Must be currently on an serotonin uptake inhibitor (to include venlafaxine or duloxetine) at an adequate dose for at least 3 weeks.
Ability and willingness to provide consent for participation in the study.

Exclusion Criteria:

Any medical condition that would preclude treatment with an SSRI, risperidone, or bupropion ER
Any clinically significant unstable medical condition
Diagnosis of bipolar disorder or a primary diagnosis of any psychotic disorder
Current psychotic symptoms (hallucination or delusions)
Alcohol or drug abuse or dependence in the last 3 months (excluding nicotine and caffeine dependence/abuse) or abuse within the last month
Documented non-response to the combination of a novel antipsychotic or bupropion ER and a SSRI
Concomitant use of any psychotropic other than an SSRI or zolpidem (PRN for sleep)
Score of 4 on the suicide item of the Ham-D scale and determination by the investigator of significant suicide risk
Known sensitivity to risperidone or bupropion ER

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00179244

Locations

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37211

Sponsors and Collaborators

Vanderbilt University

Janssen Pharmaceutica N.V., Belgium

Investigators

Principal Investigator:

Richard C Shelton, MD

Vanderbilt University

More Information

No publications provided

Study ID Numbers:	RIS vs. BUP Augmentation Depr., 040309
Study First Received:	September 13, 2005
Last Updated:	January 31, 2008
ClinicalTrials.gov Identifier:	NCT00179244 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Vanderbilt University:

Treatment Resistant Depression

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Antagonists
Mental Disorders
Therapeutic Uses
Antidepressive Agents, Second-Generation
Antidepressive Agents
Depression
Tranquilizing Agents

Risperidone
Central Nervous System Depressants
Dopamine Antagonists
Depressive Disorder
Antipsychotic Agents
Pharmacologic Actions
Behavioral Symptoms
Serotonin Agents
Bupropion
Mood Disorders
Dopamine Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on November 22, 2009